| scholarly article | Q13442814 |
| P50 | author | Robert D. Gibbons | Q46996511 |
| Bennett L Leventhal | Q61050525 | ||
| Edwin H Cook | Q41878494 | ||
| P2093 | author name string | Jeff Salt | |
| Camille W Brune | |||
| Thomas Owley | |||
| Laura Walton | |||
| Nelson Ayuyao | |||
| Steve Guter | |||
| P2860 | cites work | Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study | Q43683497 |
| Transmission disequilibrium mapping at the serotonin transporter gene (SLC6A4) region in autistic disorder | Q43937693 | ||
| Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement | Q44206567 | ||
| Use of citalopram in pervasive developmental disorders | Q44401436 | ||
| Sertraline response in adults with mental retardation and autistic disorder. | Q44443091 | ||
| Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial | Q44488828 | ||
| A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism | Q45189223 | ||
| An open-label trial of escitalopram in pervasive developmental disorders | Q46396057 | ||
| Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism | Q46666799 | ||
| Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder | Q47806910 | ||
| A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder | Q50302925 | ||
| Combining information from multiple sources in the diagnosis of autism spectrum disorders | Q50302983 | ||
| Fluoxetine Treatment of Children and Adults with Autistic Disorder and Mental Retardation | Q50305499 | ||
| Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials | Q51825239 | ||
| The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects | Q52089728 | ||
| Role of serotonergic gene polymorphisms on response to transcranial magnetic stimulation in depression | Q58795179 | ||
| Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders | Q27861089 | ||
| Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism | Q28247116 | ||
| Random-effects models for longitudinal data | Q28279619 | ||
| Clonidine treatment of hyperactive and impulsive children with autistic disorder | Q28318016 | ||
| The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism | Q29547456 | ||
| Missing Data in Longitudinal Trials - Part B, Analytic Issues | Q33492294 | ||
| Missing Data in Longitudinal Clinical Trials Part A: Design and Conceptual Issues | Q33503655 | ||
| Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. | Q33837479 | ||
| Allelic variation of human serotonin transporter gene expression | Q34379938 | ||
| The use of selective serotonin reuptake inhibitors in autism and related disorders | Q34504149 | ||
| Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder | Q34658088 | ||
| Contribution of allelic variations in transporters to the phenotype of drug response | Q36511673 | ||
| Molecular genetics of the platelet serotonin system in first-degree relatives of patients with autism | Q37337244 | ||
| Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. | Q43629967 | ||
| P433 | issue | 1 | |
| P921 | main subject | autism | Q38404 |
| escitalopram | Q423757 | ||
| autism spectrum disorder | Q1436063 | ||
| P304 | page(s) | 1-7 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | Autism Research | Q15750526 |
| P1476 | title | A pharmacogenetic study of escitalopram in autism spectrum disorders | |
| P478 | volume | 3 |
| Q50346594 | A Systems Approach Towards an Understanding, Diagnosis and Personalized Treatment of Autism Spectrum Disorders |
| Q28236081 | A new synaptic player leading to autism risk: Met receptor tyrosine kinase |
| Q39197183 | Clinically relevant pharmacogenomic testing in pediatric practice |
| Q52680610 | De novo unbalanced translocation (4p duplication/8p deletion) in a patient with autism, OCD, and overgrowth syndrome |
| Q28396362 | Differences in BTBR T+ tf/J and C57BL/6J mice on probabilistic reversal learning and stereotyped behaviors |
| Q36113601 | Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder |
| Q48580237 | Moral and Social Reasoning in Autism Spectrum Disorders |
| Q28392225 | Oxotremorine treatment reduces repetitive behaviors in BTBR T+ tf/J mice |
| Q35009426 | Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders |
| Q35982186 | Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism |
| Q38270928 | Pharmacogenomic medicine in autism: challenges and opportunities |
| Q35937022 | The selective serotonin reuptake inhibitor, escitalopram, enhances inhibition of prepotent responding and spatial reversal learning |
Search more.